Schaeffer's Top Stock Picks for '25

3 Biotechs Getting Blasted

The post-earnings price action on bluebird bio Inc (BLUE), Celgene Corporation (CELG), and Lannett Company, Inc. (LCI) has been positively brutal

Nov 5, 2015 at 11:26 AM
facebook X logo linkedin


While much of Wall Street is drooling over Facebook Inc's (NASDAQ:FB) latest earnings report, the opposite is true regarding a trio of drugmakers that just exited the confessional. Specifically, traders are panning quarterly results from bluebird bio Inc (NASDAQ:BLUE), Celgene Corporation (NASDAQ:CELG), and Lannett Company, Inc. (NYSE:LCI), which are all sharply lower at midday. Here's a closer look at what's happening on the charts and beyond.

BLUE has surrendered 19.6% of its value today to trade at $72.48, and has now lost almost one-fifth of its value on a year-to-date basis. The technical beat-down comes on the heels of a wider-than-forecast third-quarter loss and huge revenue miss, hurt by an amendment to a collaboration with CELG -- under which bluebird bio Inc re-acquired rights to its CAR T-cell therapy. Today's bearish gap should cheer the spirits of option bears. BLUE's Schaeffer's put/call open interest ratio (SOIR) of 0.85 ranks in the high 88th percentile of its annual range, indicating short-term speculators are more put-heavy than usual. On the other hand, analysts may want to reconsider their upbeat take on the equity, as every single covering firm has doled out a "buy" or better assessment.

CELG has plunged 5.5% to trade at $120.17, after the gene therapy developer's quarterly profit beat the consensus estimate by its smallest margin in nearly two years, and revenue grew at the slowest rate in five quarters due to cooling demand for its cancer treatment Revlimid. As such, the stock is on track to close below its 20-day moving average for the first time since mid-October. If Celgene Corporation extends today's losses, things could get ugly. In particular, the shares are vulnerable to downgrades, considering 12 of 14 analysts rate them a "buy" or better, with not a single "sell" opinion in sight. Plus, CELG's consensus 12-month price target of $147.47 stands in never-before-seen territory, suggesting price-target reductions are a possibility.

LCI has surrendered one-fifth of its value, last seen at $36.75 -- and fresh off an annual low of $36.40. Sparking the sell-off is a 5% drop in fiscal first-quarter profit, which prompted Craig-Hallum to cut its rating to "hold" from "buy," and Roth Capital to trim its price target to $47. Short sellers have been banking on Lannett Company, Inc. to tumble. A mind-bending 42% of the stock's float is sold short, representing roughly nine days of trading activity, at typical volumes.
 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter